Conference Coverage
Conference Coverage
Lupus patients may be shortchanged on lipid management
WASHINGTON
Conference Coverage
Tocilizumab raises cholesterol, but not cardiovascular events
WASHINGTON
Conference Coverage
Diabetes treatment costs doubled in Sweden since 2006
The cost of treating type 2 diabetes in Sweden doubled from 2006 to 2014.
Conference Coverage
Sutureless aortic valve replacement: Is ease worth the cost?
CHICAGO – Rapid deployment sutureless valves can be a good option for some patients, providing a highly functional and nearly leakproof valve with...
Conference Coverage
Aspirin use linked to increased ICH in trauma patients
WAIKOLOA, HAWAII – Among a group of anticoagulated trauma patients, those on aspirin had the highest rate and risk of intracranial hemorrhage,...
Conference Coverage
Dementia prevalence increased in heart failure patients
NEW ORLEANS - Elderly patients with heart failure had a significantly increased prevalence of both dementia and mild cognitive impairment,...
Conference Coverage
First-in-kind study parsed risks of central lines in children
SAN DIEGO - Rising rates of pediatric venous thromboembolism in the United States underscore the need to carefully weigh the risks and benefits of...
Conference Coverage
Observational hospital stays for HF linked to worse outcomes
NEW ORLEANS – Heart failure patients admitted as inpatients had significantly better outcomes than those admitted for an observational stay.
Conference Coverage
U.S. okay looms for third drug-coated PAD balloon
WASHINGTON - Good pivotal-trial performance of a drug-coated balloon for treating superficial femoral and popliteal artery stenoses raised the...
Conference Coverage
TAVR valve durability supported in large follow-up
The largest follow-up study of patients who underwent transcatheter aortic valve replacement and systematic echocardiography surveillance found a...
Conference Coverage
VIDEO: MILANO-PILOT marks end of the road for HDL mimetic
Among 120 patients with recent acute coronary syndrome, a mimetic known as MDCO-216 was no better than placebo at reducing coronary plaque...